STOCK TITAN

Farallon funds update Tango Therapeutics (TNGX) 13G with 9.99% cap

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Tango Therapeutics, Inc. received an amended Schedule 13G showing updated ownership by funds managed by Farallon Capital. As of the reporting date, the Farallon Funds hold 13,391,411 common shares and 2,159,792 pre-funded warrants, each warrant exercisable into one share.

The warrants are subject to a 9.99% Beneficial Ownership Limitation, so only 69,804 warrants are currently counted as exercisable within 60 days when calculating beneficial ownership. The amendment also records governance changes at Farallon: Avner A. Husen became a member/manager of the related general partners effective January 1, 2026, while Richard B. Fried, Rajiv A. Patel and William Seybold ceased those roles as of December 31, 2025, and may no longer be deemed beneficial owners. The filing is made on a passive basis under Rule 13d-1(c), with the group certifying the holdings are not for the purpose of changing or influencing control of Tango Therapeutics.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Farallon Capital Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:02/06/2026
Farallon Capital Institutional Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:02/06/2026
Farallon Capital Institutional Partners II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:02/06/2026
Farallon Capital Institutional Partners III, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:02/06/2026
Four Crossings Institutional Partners V, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager of its General Partner
Date:02/06/2026
Farallon Capital Offshore Investors II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:02/06/2026
Farallon Capital (AM) Investors, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:02/06/2026
Farallon Capital F5 Master I, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager of its General Partner
Date:02/06/2026
Farallon Healthcare Partners Master, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager of its General Partner
Date:02/06/2026
Farallon Partners, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member
Date:02/06/2026
Farallon Institutional (GP) V, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager
Date:02/06/2026
Farallon F5 (GP), L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager
Date:02/06/2026
Farallon Healthcare Partners (GP), L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager
Date:02/06/2026
Dapice Joshua J.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/06/2026
Dreyfuss, Philip D.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/06/2026
Dunn Hannah E.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn
Date:02/06/2026
Fried, Richard B
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/06/2026
Gehani, Varun N.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/06/2026
Giauque, Nicolas
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/06/2026
Husen, Avner A.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/06/2026
Kim, David T.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/06/2026
Linn, Michael G.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/06/2026
Luo Patrick (Cheng)
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/06/2026
Patel, Rajiv A.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/06/2026
Roberts, Jr., Thomas G.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/06/2026
Saito Edric C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/06/2026
Seybold, William
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/06/2026
Short Daniel S.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/06/2026
Spokes, Andrew J. M.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/06/2026
Warren, John R.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/06/2026
Wehrly, Mark C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:02/06/2026
Exhibit Information

Exhibit 1. Joint Acquisition Statement Pursuant to Section 240.13d-1(k)

FAQ

What does the Farallon Schedule 13G/A reveal about Tango Therapeutics (TNGX) ownership?

The filing shows Farallon-managed funds as significant holders of Tango Therapeutics common stock and pre-funded warrants. They report 13,391,411 shares plus 2,159,792 warrants, subject to a 9.99% beneficial ownership cap under the warrant terms and Section 13(d) rules.

How many Tango Therapeutics shares and warrants do the Farallon Funds report owning?

The Farallon Funds report holding 13,391,411 Tango Therapeutics common shares and 2,159,792 pre-funded common stock purchase warrants. Each warrant can be exercised into one share, but exercise is limited by a 9.99% Beneficial Ownership Limitation embedded in the warrant terms.

What is the 9.99% Beneficial Ownership Limitation mentioned for Tango Therapeutics (TNGX)?

The 9.99% Beneficial Ownership Limitation restricts warrant exercises so Farallon’s beneficial ownership does not exceed 9.99% of outstanding shares. Because of this cap, only 69,804 warrants are treated as exercisable within 60 days for beneficial ownership calculations in the filing.

Did the Farallon Schedule 13G/A indicate any attempt to influence control of Tango Therapeutics?

The certification states the securities were not acquired or held to change or influence control of Tango Therapeutics. The holders filed under Rule 13d-1(c) and describe their position as passive, aside from activities tied to proxy nomination rules referenced in the certification.

What management changes at Farallon are disclosed in this Tango Therapeutics ownership filing?

The amendment adds Avner A. Husen as a member/manager of several Farallon general partners from January 1, 2026. It also notes that Richard B. Fried, Rajiv A. Patel and William Seybold ceased those roles on December 31, 2025, and may no longer be deemed beneficial owners.

Which Farallon entities are listed as reporting persons for Tango Therapeutics (TNGX)?

Multiple Farallon funds and general partners are reporting persons, including Farallon Capital Partners, Farallon Capital Institutional Partners vehicles, offshore and healthcare funds, and Farallon Partners, L.L.C. A group of Farallon individual managing members is also listed as potentially deemed beneficial owners of the funds’ holdings.
Tango Therapeutics Inc

NASDAQ:TNGX

TNGX Rankings

TNGX Latest News

TNGX Latest SEC Filings

TNGX Stock Data

1.61B
127.57M
12.26%
109.5%
22.83%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON